BTIG raised the firm’s price target on Personalis (PSNL) to $8 from $7 and keeps a Buy rating on the shares ahead of the Q2 earnings report. The firm is positive on the SMID cap diagnostics and specialty clinical lab group, but favors mostly the labs over tools companies, where there is a clear path of expansion in gross margins and lift in cash flow, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSNL:
- Closing Bell Movers: Ultragenyx slumps 25% on UX143 recommendation
- Personalis Expands Agreement with Tempus AI for Cancer Test
- Personalis expands Tempus AI strategic collaboration
- Personalis’ NeXT Personal predicts cervical cancer recurrence risk
- Personalis presents new clinical results from PREDICT DNA and SCANDARE studies